Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PharmGKB summary: Efavirenz pathway, pharmacokinetics.

× No keyword cloud information.

61 in total

1. Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection.

Authors: Y Jamshidi; M Moreton; D A McKeown; S Andrews; T Nithiyananthan; L Tinworth; D W Holt; S T Sadiq
Journal: J Antimicrob Chemother Date: 2010-10-14 Impact factor: 5.790

2. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients.

Authors: E Ngaimisi; S Mugusi; O M Minzi; P Sasi; K-D Riedel; A Suda; N Ueda; M Janabi; F Mugusi; W E Haefeli; J Burhenne; E Aklillu
Journal: Clin Pharmacol Ther Date: 2010-09-29 Impact factor: 6.875

3. CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment.

Authors: Rajeev K Mehlotra; Moses J Bockarie; Peter A Zimmerman
Journal: Br J Clin Pharmacol Date: 2007-03-28 Impact factor: 4.335

4. Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?

Authors: Sara Colombo; Amalio Telenti; Thierry Buclin; Hansjakob Furrer; Belle L Lee; Jérôme Biollaz; Laurent A Decosterd
Journal: Ther Drug Monit Date: 2006-06 Impact factor: 3.681

5. Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz.

Authors: A E Mutlib; H Chen; G A Nemeth; J A Markwalder; S P Seitz; L S Gan; D D Christ
Journal: Drug Metab Dispos Date: 1999-11 Impact factor: 3.922

6. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients.

Authors: Abiy Habtewold; Wondwossen Amogne; Eyasu Makonnen; Getnet Yimer; Klaus-Dieter Riedel; Nobuhisa Ueda; Alemayehu Worku; Walter Emil Haefeli; Lars Lindquist; Getachew Aderaye; Jürgen Burhenne; Eleni Aklillu
Journal: J Antimicrob Chemother Date: 2011-08-16 Impact factor: 5.790

7. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.

Authors: David W Haas; Laura M Smeaton; Robert W Shafer; Gregory K Robbins; Gene D Morse; Line Labbe; Grant R Wilkinson; David B Clifford; Richard T D'Aquila; Victor De Gruttola; Richard B Pollard; Thomas C Merigan; Martin S Hirsch; Alfred L George; John P Donahue; Richard B Kim
Journal: J Infect Dis Date: 2005-11-01 Impact factor: 5.226

8. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.

Authors: David W Haas; Awewura Kwara; Danielle M Richardson; Paxton Baker; Ioannis Papageorgiou; Edward P Acosta; Gene D Morse; Michael H Court
Journal: J Antimicrob Chemother Date: 2014-04-11 Impact factor: 5.790

9. Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults.

Authors: Chonlaphat Sukasem; Montri Chamnanphon; Napatrupron Koomdee; Siwalee Santon; Thawinee Jantararoungtong; Santirat Prommas; Apichaya Puangpetch; Weerawat Manosuthi
Journal: Drug Metab Pharmacokinet Date: 2014-01-28 Impact factor: 3.614

10. Underlying genetic structure impacts the association between CYP2B6 polymorphisms and response to efavirenz and nevirapine.

Authors: Melissa A Frasco; Wendy J Mack; David Van Den Berg; Bradley E Aouizerat; Kathryn Anastos; Mardge Cohen; Jack De Hovitz; Elizabeth T Golub; Ruth M Greenblatt; Chenglong Liu; David V Conti; Celeste L Pearce
Journal: AIDS Date: 2012-10-23 Impact factor: 4.177

14 in total

1. Brief Report: Rate of Nicotine Metabolism and Tobacco Use Among Persons With HIV: Implications for Treatment and Research.

Authors: Robert A Schnoll; Morgan Thompson; Katrina Serrano; Frank Leone; David Metzger; Ian Frank; Robert Gross; Karam Mounzer; Rachel F Tyndale; Jessica Weisbrot; Miles Meline; Ronald G Collman; Rebecca L Ashare
Journal: J Acquir Immune Defic Syndr Date: 2019-02-01 Impact factor: 3.731

2. Differences in the rate of nicotine metabolism among smokers with and without HIV.

Authors: Rebecca L Ashare; Morgan Thompson; Frank Leone; David Metzger; Robert Gross; Karam Mounzer; Rachel F Tyndale; Caryn Lerman; Martin C Mahoney; Paul Cinciripini; Tony P George; Ronald G Collman; Robert Schnoll
Journal: AIDS Date: 2019-05-01 Impact factor: 4.177

3. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.

Authors: Zeruesenay Desta; Roseann S Gammal; Li Gong; Michelle Whirl-Carrillo; Aditya H Gaur; Chonlaphat Sukasem; Jennifer Hockings; Alan Myers; Marelize Swart; Rachel F Tyndale; Collen Masimirembwa; Otito F Iwuchukwu; Sanika Chirwa; Jeffrey Lennox; Andrea Gaedigk; Teri E Klein; David W Haas
Journal: Clin Pharmacol Ther Date: 2019-07-05 Impact factor: 6.875

Review 4. Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies.

Authors: Mohitosh Biswas; Nares Sawajan; Thanyada Rungrotmongkol; Kamonpan Sanachai; Maliheh Ershadian; Chonlaphat Sukasem
Journal: Front Pharmacol Date: 2022-02-18 Impact factor: 5.810

Review 5. Bidirectional Associations among Nicotine and Tobacco Smoke, NeuroHIV, and Antiretroviral Therapy.

Authors: Shivesh Ghura; Robert Gross; Kelly Jordan-Sciutto; Jacob Dubroff; Robert Schnoll; Ronald G Collman; Rebecca L Ashare
Journal: J Neuroimmune Pharmacol Date: 2019-12-13 Impact factor: 4.147

6. Pharmacokinetics and phenotyping properties of the Basel phenotyping cocktail combination capsule in healthy male adults.

Authors: Claudia Suenderhauf; Benjamin Berger; Maxim Puchkov; Yasmin Schmid; Sabine Müller; Jörg Huwyler; Manuel Haschke; Stephan Krähenbühl; Urs Duthaler
Journal: Br J Clin Pharmacol Date: 2019-12-12 Impact factor: 4.335

7. Brief Report: Nicotine Metabolism Ratio Increases in HIV-Positive Smokers on Effective Antiretroviral Therapy: A Cohort Study.

Authors: Cedric H Bien-Gund; Warren Bilker; Robert A Schnoll; Rachel F Tyndale; Joshua I Ho; Remy Bremner; Rebecca L Ashare; Robert Gross
Journal: J Acquir Immune Defic Syndr Date: 2022-04-01 Impact factor: 3.771

8. Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype.

Authors: Eliford Ngaimisi Kitabi; Omary Mashiku Sylivester Minzi; Sabina Mugusi; Philip Sasi; Mohamed Janabi; Ferdinand Mugusi; Leif Bertilsson; Jürgen Burhenne; Eleni Aklillu
Journal: Sci Rep Date: 2018-11-05 Impact factor: 4.379

9. Tryptophan metabolism and its relationship with central nervous system toxicity in people living with HIV switching from efavirenz to dolutegravir.

Authors: Michael R Keegan; Alan Winston; Chris Higgs; Dietmar Fuchs; Adriano Boasso; Mark Nelson
Journal: J Neurovirol Date: 2018-11-26 Impact factor: 2.643

10. Particle Forming Amorphous Solid Dispersions: A Mechanistic Randomized Pharmacokinetic Study in Humans.

Authors: Andreas Schittny; Samuel Waldner; Urs Duthaler; Alexander Vorobyev; Rimma Abramovich; Stephan Krähenbühl; Maxim Puchkov; Jörg Huwyler
Journal: Pharmaceutics Date: 2021-03-17 Impact factor: 6.321